Survodutide shows no increase in heart events in SYNCHRONIZE-CVOT trial

Results from the SYNCHRONIZE-CVOT trial (AHA 2026, The Lancet) show survodutide, a weekly glucagon/GLP-1 shot, did not increase heart events versus placebo in 5,530 adults with obesity or overweight and higher heart risk.

Detected & updated continuously · Source: Nebula